cytarabine has been researched along with Bilirubinemia in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (12.50) | 18.7374 |
| 1990's | 2 (12.50) | 18.2507 |
| 2000's | 7 (43.75) | 29.6817 |
| 2010's | 3 (18.75) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, A; Masadeh, M; Murali, AR | 1 |
| Gollol Raju, NS; Jayananda, S; Khalid, H; Muzaffar, M | 1 |
| Bekele, N; Borthakur, G; Estey, E; Jabbour, EJ; Kantarjian, H; Keating, MJ; O'Brien, S; Plunkett, WK; Ravandi-Kashani, F; Tsimberidou, AM | 1 |
| Amadori, S; de Witte, T; Halkes, CJ; Karrasch, M; Marie, JP; Meert, L; Meloni, G; Muus, P; Rapion, J; Suciu, S; Vignetti, M; Willemze, R | 1 |
| Altman, JK; Arellano, M; Foss, Ø; Gianella-Borradori, A; Giles, FJ; Gobbi, M; Hills, R; Jacobsen, TF; Montesinos, P; O'Connell, C; Pigneux, A; Roboz, GJ; Rosenblat, T; Solomon, SR; Vetrhusand, S; Vey, N | 1 |
| Corallo, CE; Coutsouvelis, J | 1 |
| Gopal, AK; McCarthy, J | 1 |
| Aledo, A; Alonzo, TA; Buxton, AB; Kobrinsky, NL; Lange, BJ; Woods, WG | 1 |
| Albitar, M; Cortes, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, H; Keating, M; O'Brien, S; Thomas, D; Tsimberidou, A; Verstovsek, S | 1 |
| Altundag, K; Altundag, O; Celik, I; Kars, A; Turker, A | 1 |
| Ahmed, T; Baskind, P; Darzynkiewicz, Z; Feldman, EJ; Goff, H; Pozzuoli, M; Santos, S; Seiter, K; Traganos, F | 1 |
| Bennett, JM; Dewald, GW; Friedenberg, WR; Hayes, FA; Hiddemann, W; Lazarus, HM; Liesveld, JL; Marsh, RD; Miller, KB; Paietta, E; Rowe, JM; Saba, HT; Young, MS | 1 |
| Balcar-Boroń, A; Nowaczyk-Michalak, A; Pilecki, O; Trybuś, L; Wysocki, M | 1 |
| Kirtley, DW; Thomas, E; Votaw, ML | 1 |
| Hashimoto, M; Hirose, S; Horie, S; Ishiyama, T; Saito, K; Seekikawa, I; Sugimoto, M; Wakabayashi, Y | 1 |
| Damon, LE; Linker, CA; Mass, R | 1 |
7 trial(s) available for cytarabine and Bilirubinemia
| Article | Year |
|---|---|
A phase I study of fludarabine, cytarabine, and oxaliplatin therapy in patients with relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; Hyperbilirubinemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine; Young Adult | 2014 |
Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): p
Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Consolidation Chemotherapy; Cytarabine; Fatigue; Female; Gastrointestinal Diseases; Humans; Hydroxyurea; Hyperbilirubinemia; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Risk; Treatment Outcome | 2014 |
International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytogenetic Analysis; Disease-Free Survival; Female; Humans; Hyperbilirubinemia; Hypercholesterolemia; International Cooperation; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Recurrence; Treatment Failure | 2014 |
Impact of granulocyte colony-stimulating factor use during induction for acute myelogenous leukemia in children: a report from the Children's Cancer Group.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Etoposide; Female; Filgrastim; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Hyperbilirubinemia; Infection Control; Length of Stay; Leukemia, Myeloid; Male; Neutropenia; Prospective Studies; Recombinant Proteins; Remission Induction; Survival Analysis; Thioguanine; Thrombocytosis; Treatment Outcome | 2002 |
Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes.
Topics: Adult; Aged; Alanine Transaminase; Aminoglycosides; Anemia, Refractory, with Excess of Blasts; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Cyclosporine; Cytarabine; Female; Gemtuzumab; Humans; Hyperbilirubinemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival; Treatment Outcome; Vidarabine | 2003 |
Phase II evaluation of a high-dose mitoxantrone based induction regimen in untreated adults with acute myeloid leukemia.
Topics: Actuarial Analysis; Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Conjunctivitis; Cytarabine; Disease-Free Survival; Etoposide; Female; Gastrointestinal Diseases; Humans; Hyperbilirubinemia; Leukemia, Myeloid; Male; Methylprednisolone; Middle Aged; Mitoxantrone; Remission Induction; Risk; Stomatitis; Stroke Volume; Survival Analysis; Survival Rate; Treatment Outcome; Tretinoin; Ventricular Dysfunction, Left | 2000 |
Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and CMML): an Eastern Cooperative Oncology Group Study.
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chemical and Drug Induced Liver Injury; Cytarabine; DNA Replication; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hyperbilirubinemia; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Pancytopenia; Pilot Projects; Recombinant Proteins; Remission Induction; S Phase; Treatment Failure | 2001 |
9 other study(ies) available for cytarabine and Bilirubinemia
| Article | Year |
|---|---|
Recurrent Isolated Hyperbilirubinemia From Drug-Induced Impaired Hepatic Bilirubin Uptake.
Topics: Antimetabolites, Antineoplastic; Bilirubin; Chemical and Drug Induced Liver Injury; Cytarabine; Diagnosis, Differential; Female; Gilbert Disease; Humans; Hyperbilirubinemia; Leukemia, Myeloid, Acute; Liver; Medication Therapy Management; Patient Care Management; Young Adult | 2020 |
Successful Rechallenge With Cytarabine After Isolated Hyperbilirubinemia: A Rarely Reported Adverse Effect.
Topics: Cytarabine; Drug-Related Side Effects and Adverse Reactions; Humans; Hyperbilirubinemia; Iatrogenic Disease | 2020 |
The management of prolonged, isolated hyperbilirubinemia following cytarabine-based chemotherapy for acute myeloid leukaemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Humans; Hyperbilirubinemia; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Time Factors | 2009 |
Successful use of full-dose dexamethasone, high-dose cytarabine, and cisplatin as part of initial therapy in non-hodgkin and hodgkin lymphoma with severe hepatic dysfunction.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Hodgkin Disease; Humans; Hyperbilirubinemia; Liver Diseases; Lymphoma, Large B-Cell, Diffuse; Male; Prognosis; Treatment Outcome | 2009 |
Isolated hyperbilirubinemia following standard dose cytosine arabinoside in a patient with relapsed acute myeloid leukemia.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Cytarabine; Female; Humans; Hyperbilirubinemia; Leukemia, Myeloid; Middle Aged; Recurrence | 2004 |
Jaundice following high--dose arabinoside cytosine in a child with acute myelogenous leukemia.
Topics: Administration, Oral; Cytarabine; Drug Administration Schedule; Female; Humans; Hyperbilirubinemia; Infant; Jaundice; Leukemia, Myeloid, Acute; Remission Induction; Remission, Spontaneous; Time Factors | 1992 |
Jaundice and hepatorenal syndrome associated with cytosine arabinoside.
Topics: Acute Kidney Injury; Adult; Chemical and Drug Induced Liver Injury; Cytarabine; Humans; Hyperbilirubinemia; Leukemia, Promyelocytic, Acute; Liver Diseases; Male | 1990 |
[Acute leukemia complicated by hyperbilirubinemia due to high dose cytosine arabinoside therapy].
Topics: Cholestasis, Intrahepatic; Cytarabine; Humans; Hyperbilirubinemia; Leukemia, Promyelocytic, Acute; Male; Middle Aged | 1989 |
The association between high-dose cytarabine neurotoxicity and renal insufficiency.
Topics: Acute Kidney Injury; Alcoholism; Cytarabine; Female; Humans; Hyperbilirubinemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Nervous System Diseases; Risk Factors | 1989 |